全文获取类型
收费全文 | 620篇 |
免费 | 38篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 6篇 |
妇产科学 | 10篇 |
基础医学 | 103篇 |
口腔科学 | 26篇 |
临床医学 | 53篇 |
内科学 | 166篇 |
皮肤病学 | 12篇 |
神经病学 | 47篇 |
特种医学 | 11篇 |
外科学 | 46篇 |
综合类 | 3篇 |
预防医学 | 25篇 |
眼科学 | 6篇 |
药学 | 56篇 |
中国医学 | 33篇 |
肿瘤学 | 67篇 |
出版年
2024年 | 1篇 |
2023年 | 5篇 |
2022年 | 9篇 |
2021年 | 21篇 |
2020年 | 16篇 |
2019年 | 21篇 |
2018年 | 27篇 |
2017年 | 17篇 |
2016年 | 16篇 |
2015年 | 28篇 |
2014年 | 19篇 |
2013年 | 38篇 |
2012年 | 65篇 |
2011年 | 69篇 |
2010年 | 35篇 |
2009年 | 24篇 |
2008年 | 41篇 |
2007年 | 41篇 |
2006年 | 38篇 |
2005年 | 24篇 |
2004年 | 23篇 |
2003年 | 25篇 |
2002年 | 11篇 |
2001年 | 15篇 |
2000年 | 12篇 |
1999年 | 11篇 |
1998年 | 5篇 |
1997年 | 1篇 |
1992年 | 2篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1977年 | 2篇 |
1976年 | 2篇 |
排序方式: 共有672条查询结果,搜索用时 0 毫秒
61.
62.
Because additive effects of inhaled corticosteroids and long-acting anticholinergics are unclear, we undertook this study to compare the efficacy of tiotropium alone and tiotropium plus budesonide in patients with chronic obstructive pulmonary disease. The study subjects were randomized to receive either tiotropium 18 microg once daily with or without budesonide 200 microg twice daily for 6 weeks. The efficacy variables were changes in trough forced expiratory volume in one second (FEV1), St. George's Respiratory Questionnaire (SGRQ), 6-minute walk distance (6MWD), and use of rescue medication. One hundred patients were randomized and 81 completed the study. The mean age was 64.0 yr, and the mean FEV1 was 39.7% predicted. Compared with tiotropium alone (N=40), the tiotropium/budesonide combination (N=41) was related to an improvement in the SGRQ total score (tiotropium -2.8 units and tiotropium/budesonide -5.6 units, p=0.003). 6MWD was improved by 13.5 m in the tiotropium group and by 22.5 m in the tiotropium/budesonide group (p=0.031). Changes in trough FEV1 and the use of rescue medication were similar between two groups. In conclusion, compared with tiotropium alone, the tiotropium/budesonide combination was related to an improved health-related quality of life. These data support that low-dose budesonide may enhance the efficacy of tiotropium. 相似文献
63.
64.
65.
Hyung Joon Yim Sang Jun Suh Soon Ho Um 《World journal of gastroenterology : WJG》2015,21(13):3826-3842
Hepatocellular carcinoma(HCC) is one of the leading causes of cancer death, especially in Eastern areas. With advancements in diagnosis and treatment modalities for HCC, the survival and prognosis of HCC patients are improving. However, treatment patterns are not uniform between areas despite efforts to promote a common protocol. Although many hepatologists in Asian countries may adopt the principles of the Barcelona Clinic Liver Cancer staging system, they are also independently making an effort to expand the indications of each treatment and to combine therapies for better outcomes. Several expanded criteria for liver transplantation in HCC have been developed in Asian countries. Living donor liver transplantation is much more commonly performed in these countries than deceased donor liver transplantation, and it may be preceded by other treatments such as the down-staging of tumors. Local ablation therapies are often combined with transarterial chemoembolization( TACE) and the outcome is comparable to that of surgical resection. The indications of TACE are expanding, and there are new types of transarterial therapies. Although data on drug-eluting beads, TACE, and radioembolization in Asian countries are still relatively sparse compared with Western countries, these methods are gradually gaining popularity because of better tolerability and the possibility of improved response rates. Hepatic arterial infusion chemotherapy and radiotherapy are not included in Western guidelines, but are currently being used actively in several Asian countries. For more advanced HCCs, appropriate combinations of TACE, radiotherapy, and sorafenib can be considered, and emerging data indicate improved outcomes of combination therapies compared with single therapies. To include these paradigm shifts into newer treatment guidelines, more studies may be needed, but they are certainly in progress. 相似文献
66.
CD10 expression is enhanced by Twist1 and associated with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro and in vivo 下载免费PDF全文
67.
Sung-Lyul Lim Sang-Yoon Park Sukmin Kang Dain Park Sung-Hoon Kim Jae-Young Um Hyeung-Jin Jang Jun-Hee Lee Chul-Ho Jeong Jung-Hee Jang Kwang Seok Ahn Seok-Geun Lee 《American journal of cancer research》2015,5(1):289-299
STAT3 has been recognized as an efficacious drug target for prostate cancer because of its constitutive activation in this fatal disease. We recently identified the root bark of Morus alba Linn. as a potential STAT3 inhibitor among 33 phytomedicines traditionally used in Korea. Morusin, an active compound isolated from the root bark of Morus alba, has shown anti-oxidant and anti-inflammatory effects. In the present study, we examined whether morusin has a potential as an anti-cancer agent in prostate cancer. We found that morusin suppressed viability of prostate cancer cells, but little effect in normal human prostate epithelial cells. Morusin also reduced STAT3 activity by inhibiting its phosphorylation, nuclear accumulation, and DNA binding activity. In addition, morusin down-regulated expression of STAT3 target genes encoding Bcl-xL, Bcl-2, Survivin, c-Myc and Cyclin D1, which are involved in regulation of apoptosis and cell cycle. Furthermore, morusin induced apoptosis in human prostate cancer cells by reducing STAT3 activity. Taken together, these results suggest that morusin could be a potentially therapeutic agent for prostate cancer by reducing STAT3 activity and inducing apoptosis. 相似文献
68.
Lee BJ Lee HS Kim CD Jung SW Seo YS Kim YS Jeen YT Chun HJ Um SH Lee SW Choi JH Ryu HS 《Gut and liver》2012,6(2):262-269
Background/Aims
Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) and peroxisome proliferator-activated receptor gamma (PPARγ) ligands can modulate cellular differentiation, proliferation, and apoptosis through various pathways. It has been shown that HMG-CoA reductase inhibitors and PPARγ agonists separately inhibit pancreatic stellate cell (PaSC) activation. We studied the effects of a combination of both types of drugs on activated PaSCs via platelet-derived growth factor (PDGF), which has not previously been reported. The present study was performed to elucidate the underlying mechanisms of these effects by focusing on the impact of the signaling associated with cell-cycle progression.Methods
Primary cultures of rat PaSCs were exposed to simvastatin and troglitazone. Proliferation was quantified using the BrdU method, and cell-cycle analysis was performed using a fluorescent activated cell sorter. The protein expression levels of smooth muscle actin (SMA), extracellular signal-regulated kinase (ERK), and a cell cycle machinery protein (p27Kip1) were investigated using Western blot analysis.Results
Simvastatin reversed the effects of PDGF on cell proliferation in a dose-dependent manner. The combination of a low concentration of simvastatin (1 mM) and troglitazone (10 mM) synergistically reversed the effects of PDGF on cell proliferation but had no effect on cell viability. The expression of a-SMA was markedly attenuated by combining the two drugs, which blocked the cell cycle beyond the G0/G1 phase by reducing the levels of phosphorylated ERK and reversed the expression of p27Kip1 interrupted by PDGF.Conclusions
Simvastatin and troglitazone synergistically inhibited cell proliferation in activated PaSCs by blocking the cell cycle beyond the G0/G1 phase. This inhibition was due to the synergistic modulation of the ERK pathway and the cell cycle machinery protein p27Kip1. 相似文献69.
Jeong Han Kim Hyung Joon Yim Kwang Gyun Lee Seung Young Kim Eun Suk Jung Young Kul Jung Ji Hoon Kim Yeon Seok Seo Jong Eun Yeon Hong Sik Lee Soon Ho Um Kwan Soo Byun Ho Sang Ryu 《Hepatology International》2012,6(2):505-510
Purpose
There have been reports that radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) is as equally effective as surgical resection for the treatment of hepatocellular carcinoma (HCC). This study aimed to evaluate recurrence rate and risk factor of recurrence after RFA combined with TACE for early stage HCC.Methods
We reviewed the medical records of the patients who were diagnosed with early stage HCC between March 2006 and August 2008 at Korea University Medical Center and treated with RFA combined with TACE for curative intent (n?=?65).Results
Recurrence rate was 40% (26 cases) and the time to recurrence was 14.9?months. Cumulative recurrence rate at 1?year was 20% (13 cases) and at 2?years was 33.8% (22 cases). Significant variables for recurrence were: (1) RFA repeated more than one session at initial therapy (P?<?0.001) and (2) size of main lesion ??2?cm (P?=?0.047).Conclusions
The recurrence rate of combination therapy was considerably high. Regardless of the therapy used, careful post-RFA follow-up is needed, especially if additional treatment is required after the first session or if the main lesion is ??2?cm at the time of RFA. 相似文献70.